The Top 10 Cardiovascular Device Companies: Market trends, growth strategies, and SWOT analyses

Date: August 22, 2010
Pages: 96
Price:
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TC9E4493E2FEN
Leaflet:

Download PDF Leaflet

The Top 10 Cardiovascular Device Companies: Market trends, growth strategies, and SWOT analyses
The cardiovascular (CV) device industry is highly competitive and has reached maturity resulting in single digit growth rates of prominent devices such as pacemakers, defibrillators, and drug eluting stents (DES). Innovations in niche sectors such as atrial fibrillation (AF) and ventricular assist devices (VADs) are poised for double digit growth in the near to mid-term future. From 2007–09, the top three companies in the CV segment acquired other smaller firms to expand their product portfolios and to gain market share in new geographies. Some major companies also established manufacturing facilities outside the US to enhance cost containment and product distribution. The CV device market remained relatively resilient during the economic downturn compared with other healthcare segments. The 2007–09 period also witnessed a considerable rise in consolidation activities among major companies.

This report provides detailed profiles of the top 10 cardiovascular (CV) device companies and brief profiles of other major players. It also elucidates trends within the cardiovascular device market. The detailed profiles contain descriptions of business, financial performance, growth strategies and SWOT analyses. The analysis is based on:
  • Each company’s consolidated and segmental financial performance;
  • Each company’s growth strategies and major acquisitions and divestments relating to the CV devices market;
  • Key partnerships and alliances formed by these companies;
  • Business-related strengths and weaknesses of these companies and insights into the opportunities and threats facing them.
Key features of this report
Drivers
  • Innovations in CRM and DES segments such as MRI compatible pacemakers from Medtronic and Abbott’s Xience drug eluting stent with their positive clinical outcomes support stronger evidence for long-term benefits.
  • Emerging markets for DES in Canada, China and parts of Asia furnish opportunities to expand businesses for CV companies.
  • Ageing population in industrialized markets such as the US, Europe and Japan are increasing. Moreover, the ICDs and pacemakers in these geographies are expected to have a second-phase of CRM implants.
Resistors
  • The safety and efficacy of DES are under scrutiny following numerous clinical studies and more studies are being executed to justify the long-term efficacy of DES intervention.
  • Markets for ICDs and pacemakers have reached maturation. ICD sales are growing between 4-5% and pacemakers between 2-3% annually.
  • Reduction in reimbursement affects sales and profitability for CV device manufacturers.
Scope of this report
  • Learn from the business operation strategies of the premier CV device companies to target future growth markets effectively, avoid their mistakes, and replicate their successes.
  • Benchmark your performance against the leading CV device companies.
  • Analyze the growth strategies of major players in the CV industry and how their business models are planned for the next 3 to 5 years.
  • Compare performances of the top 10 companies in the CV market with respect to acquisitions, new product innovation, geographic expansion, and industry challenges.
  • Save time, money and resources on analyzing the performance of leading CV device companies using this report.
Key Market Issues

Pricing pressures due to industry regulations

The CV device industry is highly regulated around the world with stringent guidelines defined by regulatory bodies. The medical device approvals by governing bodies such as the FDA in the US have become very meticulous that CV device manufacturers are launching products outside the US such as Europe and Canada. Since the prices are strictly regulated outside the US, manufacturers will be forced to launch their products in the US for a similar price. In the long run, the pricing pressures would continue to prevail and limit the profitability margins for CV device manufacturers.

Significance of CV device innovation

Markets reaching saturation for major revenue generators in the CV device segment such as ICD, pacemaker and DES. New device innovation will be the only parameter that will assure a company of its competitive edge. Novel technologies that are uncontested would help a company by allowing it to charge premium pricing. Research & development (R&D) initiatives and interdisciplinary knowledge will remain the benchmark for assuring a company’s success and commanding prevalence in the market.

Decline in capital expenditure of hospitals

In the US, hospitals spend a considerable amount of their revenues on capital expenditure to improve their facilities and purchase new medical technology. However, the impact of economic recession since 2008 had forced hospitals to decrease their capital expenditure by almost 6%. This decline will impact the medical devices industry across all sectors in the CV device division. Some segments of the CV device industry such as ICD, pacemakers, heart valves and stents will remain insulated from the economic impact given their non-elective nature of associated procedures. other low budget, high-frequency CV accessories that hospitals purchases on a regular basis will be affected due to decline of capital expenditures.

Key findings from this report
  • The top 10 companies had cumulative revenues of $27bn in 2009 and over 95% share of the global CV device market. The top 3 CV device companies dominate more than 60% of this segment’s market share.
  • Medtronic was the No. 1 company with CV device revenues of $8.6bn in 2009. The company strategically acquired other franchises to expand its heart valve and catheter product portfolios.
  • The growth rates of the implantable cardioverter defibrillator (ICD) and pacemaker sectors in 2009 were 4–5% and 2–3% respectively. The ventricular assist device (VAD) and atrial fibrillation (AF) sectors are poised for double-digit growth rates over the next 2–3 years.
  • Business Insights’ analysis revealed that, even during economic recession, the CV device market has remained buoyant, achieving single-digit growth. However, the growth rate in this segment – with the exception of AF solutions and VAD sales – will remain in the mid single digits over the next decade.
Key questions answered
  • What was the market value of the global CV device industry in 2009?
  • What are the global market values for the major CV device segments?
  • What are the key trends in the CV device industry and what are the leading companies’ strategic responses?
  • Who are the major players in the global CV device market?
  • What are the growth strategies of the leading CV device companies?

About Business Insights
Disclaimer
Executive summary
Industry overview
Medtronic
Boston Scientific
St. Jude Medical
Abbott Laboratories
Cordis
Terumo
Edwards Lifesciences
Sorin
Zoll Medical
Thoratec

CHAPTER 1 INTRODUCTION

What is this report about?
Methodology

CHAPTER 2 INDUSTRY OVERVIEW

Summary
Introduction
Market size and growth
Key drivers and resistors
Drivers of growth
Resistors of growth
Competitive landscape
The top 10 companies
Market characteristics
CV industry trends
Pricing pressures due to industry regulations
Significance of CV device innovation
Decline in capital expenditure of hospitals
Cost containment challenges

CHAPTER 3 MEDTRONIC

Summary
Company overview
Financial performance
Financial performance by segments
Cardiac rhythm management
Cardiovascular
Physio-control
Marketed products
Cardiac rhythm management
Cardiovascular
Physio-control
Recent product approvals
Challenges
Litigations
Growth strategies
Research and development
Acquisitions
Analysis of growth strategies
Marketing and sales strategies
SWOT analysis - Medtronic

CHAPTER 4 BOSTON SCIENTIFIC

Summary
Company overview
Financial performance
Marketed products
Recently launched products and approvals
Challenges
Litigations
Growth strategies
Research and development
Analysis of growth strategies
SWOT analysis - Boston Scientific

CHAPTER 5 ST. JUDE MEDICAL

Summary
Company overview
Financial performance
Financial performance by segments
Marketed products
Recent approvals and product launches
Growth strategies
Research and development
Analysis of growth strategies
SWOT analysis - St. Jude Medical

CHAPTER 6 ABBOTT LABORATORIES

Summary
Company overview
Financial performance
Marketed products
Recent approvals and product launches
Growth strategies
Acquisitions and divestments
Analysis of growth strategies
SWOT analysis - Abbott Laboratories

CHAPTER 7 CORDIS

Summary
Company overview
Financial performance
Marketed products
Recent approvals and product launches
Challenges
Litigations
Growth strategies
Research and development
Analysis of growth strategies
SWOT analysis - Cordis

CHAPTER 8 TERUMO

Summary
Company overview
Financial performance
Marketed products
Recent approvals and product launches
Growth strategies
Research and development
Analysis of growth strategies
SWOT analysis - Terumo

CHAPTER 9 EDWARDS LIFESCIENCES

Summary
Company overview
Financial performance
Financial performance by segments
Heart valve therapy
Cardiac surgery systems
Vascular
Marketed products
Recent approvals and product launches
Challenges
Litigations
Growth strategies
Research and development
Analysis of growth strategies
SWOT analysis - Edwards Lifesciences

CHAPTER 10 SORIN

Summary
Company overview
Financial performance
Financial performance by segments
Marketed products
Recent approvals and product launches
Growth strategies
Analysis of growth strategies
SWOT analysis - Sorin

CHAPTER 11 ZOLL MEDICAL

Summary
Company overview
Financial performance
Marketed products
Recent approvals and product launches
Growth strategies
Research and development
Analysis of growth strategies
SWOT analysis - Zoll Medical

CHAPTER 12 THORATEC

Summary
Company overview
Financial performance
Marketed products
Recent approvals and product launches
Growth strategies
Research and development
Analysis of growth strategies
SWOT analysis - Thoratec

CHAPTER 13 OTHER MAJOR PLAYERS

Merit Medical Systems
ATS Medical
Biotronik
Appendix
Abbreviations
Definitions

TABLE OF FIGURES

Figure 1: CV device global market performance, 2007–2009
Figure 2: Revenues of top 10 CV companies ($m), 2007-2009
Figure 3: Medtronic CV device revenue performance, 2007–09
Figure 4: SWOT analysis – Medtronic
Figure 5: Boston Scientific CV device revenue performance, 2007–09
Figure 6: SWOT analysis – Boston Scientific
Figure 7: St. Jude Medical CV device revenue performance, 2007–09
Figure 8: SWOT analysis – St. Jude Medical
Figure 9: Abbott Laboratories CV device revenue performance, 2007–09
Figure 10: SWOT analysis – Abbott Laboratories
Figure 11: Cordis CV device revenue performance, 2007–09
Figure 12: SWOT analysis – Cordis
Figure 13: Terumo CV device revenue performance, 2007–09
Figure 14: SWOT analysis – Terumo
Figure 15: Edwards Lifesciences CV device revenue performance, 2007–09
Figure 16: SWOT analysis – Edwards Lifesciences
Figure 17: Sorin CV device revenue performance, 2007–09
Figure 18: SWOT analysis – Sorin
Figure 19: Zoll Medical CV device revenue performance, 2007–09
Figure 20: SWOT analysis – Zoll
Figure 21: Thoratec CV device revenue performance, 2007–09
Figure 22: SWOT analysis – Thoratec
Figure 23: Merit Medical Systems CV device revenue performance, 2007–09
Figure 24: ATS Medical CV device revenue performance, 2007–09

TABLE OF TABLES

Table 1: CV device global market performance, 2007–2009
Table 2: Revenues of top 10 cardiovascular companies ($m), 2007-2000
Table 3: Global market shares of the top 10 CV device companies, 2009
Table 4: R&D expenditure of top 3 CV device companies, 2009
Table 5: Global market size of prominent CV device segments, 2009
Table 6: Medtronic CV device revenue performance, 2007–09
Table 7: Medtronic product portfolio
Table 8: Boston Scientific CV device revenue performance, 2007–09
Table 9: Boston Scientific product portfolio
Table 10: St. Jude Medical CV device revenue performance, 2007–09
Table 11: St. Jude Medical product portfolio
Table 12: Abbott Laboratories CV device revenue performance, 2007–09
Table 13: Abbott Laboratories product portfolio
Table 14: Cordis CV device revenue performance, 2007–09
Table 15: Cordis product portfolio
Table 16: Terumo CV device revenue performance, 2007–09
Table 17: Terumo product portfolio
Table 18: Edwards Lifesciences CV device revenue performance, 2007–09
Table 19: Edwards Lifesciences product portfolio
Table 20: Sorin CV device revenue performance, 2007–09
Table 21: Sorin product portfolio
Table 22: Zoll Medical CV device revenue performance, 2007–09
Table 23: Zoll Medical product portfolio
Table 24: Thoratec CV device revenue performance, 2007–09
Table 25: Thoratec product portfolio
Table 26: Merit Medical Systems CV device revenue performance, 2007–09
Table 27: ATS Medical CV device revenue performance, 2007–09
Skip to top


Ask Your Question

The Top 10 Cardiovascular Device Companies: Market trends, growth strategies, and SWOT analyses
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: